First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Pocenbrodib targets CREBBP/EP300 proteins, inhibiting cancer cell growth in mCRPC, with promising results from the COURAGE study. The trial includes monotherapy and combination therapy arms, focusing ...

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, ...

Pocenbrodib works by inhibiting CREBBP/EP300 (also known as CBP/p300), which are proteins that activate genes that promote cancer cell growth and proliferation. Inhibiting these proteins impacts the ...

Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds reported to be useful for the treatment of cancer, autoimmune and ...

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence ...

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced ...

目前，针对 COVID-19 的治疗手段仍在不断探索中。阿奇霉素（AZM）作为一种广泛应用的抗生素，因其独特的药理机制，在治疗 SARS-CoV-2 感染方面受到了越来越多的关注。然而，其在 COPD 和 IPF 患者中的治疗效果和作用机制尚不明确。为了填补这一空白，来自广州红十字会医院（暨南大学）等机构的研究人员开展了一项重要研究，相关成果发表在《Scientific Reports》上。